Treatment of severe chronic idiopathic urticaria with oral mycophenolate mofetil in patients not responding to antihistamines and/or corticosteroids

International Journal of Dermatology

Volumn 45, Issue 10, 2006, Pages 1224-1227

  Shahar, Eduardo ^a,b   Bergman, Reuven ^a,b   Guttman Yassky, Emma ^a,b   Pollack, Shimon ^a,b  

^a RAMBAM MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOMODULATING AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; ARTICLE; CHRONIC URTICARIA; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; IDIOPATHIC DISEASE; MALE; OPEN STUDY; PRURITUS; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; URTICARIA;

EID: 33749853951     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2006.02655.x     Document Type: Article

References (18)

1. O'Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on quality of life. Br J Dermatol 1997; 136: 553-556.
2. Middleton's Allergy: Principle and Practice, 6th edn. Mosby: Elsevier, 2003: 1551-1559.
3. Greaves MW. Pathophysiology of chronic urticaria. Int Arch Allergy Appl Immunol 2002; 127: 3-9.
4. Humphreys F, Hunter JAA. The characteristics of urticaria in 390 patients. Br J Dermatol 1998; 138: 635-638.
5. Kaplan AP. Chronic urticaria and angioedema. N Engl J Med 2002; 946: 175-179.
6. Grattan CEH, O'Donnell BF, Francis DM, et al. Randomized double-blind study of cyclosporine in chronic idiopathic urticaria. Br J Dermatol 2000; 143: 365-372.
7. Tedeschi A, Airaghi L, Lorini M, et al. Chronic urticaria: A role for newer immunomodulatory drugs? Am J Clin Dermatol 2003; 4: 297-305.
8. Simons FE, Sussman GL, Simons KJ. Effect of the H2-antagonist cimetidine on the pharmacokinetics and pharmacodynamics of the H1-antagonists hydroxyzine and cetirizine in patients with chronic urticaria. Allergy Clin Immunol 1995; 95: 685-693.
9. Cusack C, Gorman DJ. Role of thyroxine in chronic urticaria and angio-oedema. J R Soc Med 2003; 96: 571.
10. Saini SS. Addition of zafirlukast to cetirizine in the treatment of chronic urticaria. Curr Allergy Asthma Rep 2004; 4: 262.
11. Moder KG. Mycophenolate mofetil: New applications for this immunosuppresant. Ann Allergy, Asthma, Immunol 2003; 90: 15-19.
12. Hansen ER, Buus S, Deleuran M, et al. Treatment of atopic dermatitis with mycophenolate mofetil. Br J Dermatol 2000; 143: 1324-1326.
13. Neuber K, Schwartz I, Itschert G, et al. Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol 2000; 143: 385-391.
14. Geilen CC, Tebbe B, García-Bartels C, et al. Successful treatment of erythrodermic psoriasis with mycophenolate mofetil. Br J Dermatol 1998; 138: 1101-1102.
15. Worm M, Sterry W, Kolde G. Mycophenolate mofetil is effective for maintenance therapy of hypocomplementaemic urticarial vasculitis. Br J Dermatol 2000; 143: 1324.
16. Nousari HC, Sragovich AS, Kimyai-Asadi A, et al. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol 1999; 40: 265-268.
17. O'Donnell BF, Barr RM, Black AK, et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol 1998; 138: 101-106.
18. Sabroe RA, Grattan CE, Francis DM, et al. The autologous serum skin test: A screening test for autoantibodies in chronic idiopathic urticaria. Br J Dermatol 1999; 140: 446-452.